Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

501. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. Full Text available with Trip Pro

Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. To assess the efficacy of three days versus five days of treatment with oral amoxicillin for curing non-severe pneumonia in children.Randomised, double blind, placebo controlled multicentre trial.Outpatient departments of seven referral hospitals in India.2188 children aged 2-59 months, 1095 given three days of treatment and 1093 given five days.Oral (...) % for three day and five day treatments, respectively. Loss to follow up was 5.4% by day 5. There were no deaths, 41 hospitalisations, and 36 minor adverse reactions. There were 225 (10.3%) clinical failures and 106 (5.3%) relapses, and rates were similar in both treatments. At enrollment, 513 (23.4%) children tested positive for respiratory syncytial virus, and Streptococcus pneumoniae and Haemophilus influenzae were isolated from the nasopharynx in 878 (40.4%) and 496 (22.8%) children, respectively

2004 BMJ Controlled trial quality: predicted high

502. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis

Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

503. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days

Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

504. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Full Text available with Trip Pro

Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of linezolid for the treatment of ventilator-associated pneumonia (VAP) caused by both methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA, respectively). The comparator used in the study was vancomycin. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population

2004 NHS Economic Evaluation Database.

505. Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals

Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals Marras T K, Jamieson L, Chan C K (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of antimicrobial guidelines for the treatment of community-acquired pneumonia (CAP) was investigated before and after their revision (1993 Canadian Thoracic and Infectious

2004 NHS Economic Evaluation Database.

506. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin

Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

507. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials

Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

508. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial

Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

509. Electronic clinical pathway for community acquired pneumonia (e-CP CAP)

Electronic clinical pathway for community acquired pneumonia (e-CP CAP) Electronic clinical pathway for community acquired pneumonia (e-CP CAP) Electronic clinical pathway for community acquired pneumonia (e-CP CAP) Usui K, Kage H, Soda M, Noda H, Ishihara T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology An electronic clinical pathway (e-CP) for community-acquired pneumonia (CAP) was examined. The pathway covered the management of medical procedures, including physical and laboratory examinations, medical care, prescriptions, diets, activities and patient education. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised hospitalised patients who

2004 NHS Economic Evaluation Database.

510. Blind and bronchoscopic sampling methods in suspected ventilator-associated pneumonia: A multicentre prospective study

Blind and bronchoscopic sampling methods in suspected ventilator-associated pneumonia: A multicentre prospective study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2004 PedsCCM Evidence-Based Journal Club

511. Community-acquired pneumonia. (Abstract)

Community-acquired pneumonia. This seminar reviews important features and management issues of community-acquired pneumonia (CAP) that are especially relevant to immunocompetent adults in light of new information about cause, clinical course, diagnostic testing, treatment, and prevention. Streptococcus pneumoniae remains the most important pathogen; however, emerging resistance of this organism to antimicrobial agents has affected empirical treatment of CAP. Atypical pathogens have been quite (...) of treatment, and decisions about specific agents are guided by several considerations that include spectrum of activity, and pharmacokinetic and pharmacodynamic principles. Several factors have been shown to be associated with a beneficial clinical outcome in patients with CAP. These factors include administration of antimicrobials in a timely manner, choice of antibiotic therapy, and the use of a critical pneumonia pathway. The appropriate use of vaccines against pneumococcal disease and influenza should

2003 Lancet

512. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. (Abstract)

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. We investigated the temporal progression of the clinical, radiological, and virological changes in a community outbreak of severe acute respiratory syndrome (SARS).We followed up 75 patients for 3 weeks managed with a standard treatment protocol of ribavirin and corticosteroids, and assessed the pattern of clinical disease, viral load, risk factors for poor clinical outcome (...) , and the usefulness of virological diagnostic methods.Fever and pneumonia initially improved but 64 (85%) patients developed recurrent fever after a mean of 8.9 (SD 3.1) days, 55 (73%) had watery diarrhoea after 7.5 (2.3) days, 60 (80%) had radiological worsening after 7.4 (2.2) days, and respiratory symptoms worsened in 34 (45%) after 8.6 (3.0) days. In 34 (45%) patients, improvement of initial pulmonary lesions was associated with appearance of new radiological lesions at other sites. Nine (12%) patients

2003 Lancet

513. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. (Abstract)

S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Pneumocystis carinii is unable to synthesise S-adenosylmethionine and thus scavenges this intermediate. We aimed to test whether measurement of concentrations of this metabolic intermediate in plasma could provide a new method for rapid diagnosis of Pneumocystis carinii pneumonia (PCP). We measured S-adenosylmethionine plasma concentrations in 12 healthy controls, 16 patients with confirmed or suspected PCP (...) , and 36 patients with other infections. Median concentration in healthy controls was 106 nmol/L (range 86-128), but the protein was undetectable in eight patients with histologically proven and seven with suspected PCP, and was 8 nmol/L in another confirmed case (p<0.0001). In 36 patients with other infections, S-adenosylmethionine concentrations were much the same as in controls: 18 had bacterial pneumonia, two tuberculosis, five cryptococcal meningitis, three had other infections, and eight had

2003 Lancet

514. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. (Abstract)

An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. In February 2002, clinicians at the Dartmouth College Health Service recognized an outbreak of conjunctivitis; cultures of conjunctival swabs implicated Streptococcus pneumoniae. An investigation was begun to determine the extent of the outbreak, confirm the cause, identify modes of transmission, and implement control measures.Investigators reviewed the health service's data base for diagnoses of conjunctivitis. Viral (...) of conjunctivitis on a college campus was caused by an atypical, unencapsulated strain of S. pneumoniae that was identical to strains that had caused outbreaks two decades earlier.Copyright 2003 Massachusetts Medical Society

2003 NEJM

515. Testing strategies in the initial management of patients with community-acquired pneumonia. (Abstract)

Testing strategies in the initial management of patients with community-acquired pneumonia. The initial management of patients suspected of having community-acquired pneumonia is challenging because of the broad range of clinical presentations, potential life-threatening nature of the illness, and associated high costs of care. The initial testing strategies should accurately establish a diagnosis and prognosis in order to determine the optimal treatment strategy. The diagnosis is important (...) in determining the need for antibiotic therapy, and the prognosis is important in determining the site of care. This paper reviews the test characteristics of the history, physical examination, and laboratory findings, individually and in combination, in diagnosing community-acquired pneumonia and predicting short-term risk for death from the infection. In addition, we consider the implications of these test characteristics from the perspective of decision thresholds. The history and physical examination

2003 Annals of Internal Medicine

516. Severe acute interstitial pneumonia and gefitinib. (Abstract)

Severe acute interstitial pneumonia and gefitinib. Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase that is an effective treatment for patients with advanced non-small cell lung cancer who do not respond to platinum-based chemotherapy. We assessed four patients who had non-small cell lung cancer causing severe acute interstitial pneumonia in association with gefitinib. Although two patients recovered after treatment with steroids, the other two (...) died from progressive respiratory dysfunction. On the basis of autopsies and bilateral distribution of diffuse ground-glass opacities in chest CTs, we diagnosed diffuse alveolar damage, which was consistent with acute interstitial pneumonia. Patients with interstitial pneumonia also had other pulmonary disorders such as previous thoracic irradiation and poor performance status. Physicians should be aware of the alveolar damage induced by gefitinib, especially for patients with these characteristic

2003 Lancet

517. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community-acquired pneumonia in children

Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community-acquired pneumonia in children Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

518. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Full Text available with Trip Pro

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. The optimal duration of antimicrobial treatment for ventilator-associated pneumonia (VAP) is unknown. Shortening the length of treatment may help to contain the emergence of multiresistant bacteria in the intensive care unit (ICU).To determine whether 8 days is as effective as 15 days of antibiotic treatment of patients with microbiologically proven VAP.Prospective, randomized

2003 JAMA Controlled trial quality: predicted high

519. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia: a systematic review

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

520. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials

Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials Sazawal S, Black R E CRD summary This review of the community-based case management (...) approach proposed by the World Health Organization for developing countries concluded that intervention reduces mortality in neonates, infants and preschool children and should be part of primary health care. Significant heterogeneity was present for some outcomes, suggesting that the results may not be generalisable. Authors' objectives To estimate the effects of the pneumonia case-management approach advised by the World Health Organization (WHO) on mortality in pre-school children. Searching MEDLINE

2003 DARE.